mdlinx mdlinx

Rheumatology - Rheumatoid Arthritis News & Articles

What you'll find here at MDLinx Rheumatology: The top rheumatology clinical articles of the day, plus MDLinx exclusive content

  • Our medical editors bring you the best key learnings published in the top peer-reviewed rheumatology medical journals. You'll find overviews here ranked and organized by topic on rheumatoid arthritis, joint and back pain, osteoarthritis, lupus and autoimmune diseases, osteoporosis and bone fractures. In a matter of minutes, you and all the members of your patient care team can stay current on the literature as it is published.
  • MDLinx exclusive content includes monthly highlights from our physician editor, D. Scott Cunningham, MD, PhD, as well as clinical pearls from The Smartest Internist, The Smartest Family Physician, and The Smartest Pediatrician daily quiz challenges.

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Articles

Latest (6) Full Text Articles (48) Focus on Osteoporosis
Ranked, sorted, and summarized by MDLinx editors from the latest literature
Topics:

541 Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial Annals of Rheumatic Diseases, January 8, 2013    Clinical Article

542 Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2) Annals of Rheumatic Diseases, January 8, 2013    Clinical Article

543 Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial Annals of Rheumatic Diseases, January 8, 2013    Clinical Article

544 Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement Annals of Rheumatic Diseases, January 8, 2013    Evidence Based Medicine

545 Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis Annals of Rheumatic Diseases, January 8, 2013    Clinical Article

546 Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial The Lancet - Early Online Publication, January 8, 2013    Clinical Article

547 Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis Annals of Rheumatic Diseases, January 8, 2013    Clinical Guideline    Clinical Article

548 3 T DCE-MRI assessment of synovitis of the interphalangeal joints in patients with erosive osteoarthritis for treatment response monitoring Skeletal Radiology, January 8, 2013    Clinical Article

549 Arthroscopic Synovectomy of the Ankle in Rheumatoid Arthritis Arthroscopy, January 8, 2013    Clinical Article

550 Rheumatoid Arthritis-Associated Corneal Ulceration: Mortality and Graft Survival Ophthalmology, January 8, 2013    Clinical Guideline    Clinical Article

551 Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis Seminars in Arthritis and Rheumatism, January 7, 2013    Evidence Based Medicine    Clinical Article

552 Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review Clinical and Experimental Rheumatology Online, January 7, 2013    Evidence Based Medicine    Clinical Article

553 Urinary tract infections in patients with rheumatoid arthritis Clinical Rheumatology, January 7, 2013    Review Article

554 Utility of combined high-resolution bone SPECT and MRI for the identification of rheumatoid arthritis patients with high-risk for erosive progression European Journal of Radiology, January 7, 2013    Clinical Article

555 Characteristics of patients with rheumatoid arthritis in clinical remission: the many aspects of DAS28 remission Clinical and Experimental Rheumatology Online, January 4, 2013    Review Article    Clinical Guideline

556 The low binding affinity of ADAMTS4 for citrullinated fibronectin may contribute to the destruction of joint cartilage in rheumatoid arthritis Clinical and Experimental Rheumatology Online, January 4, 2013    Clinical Guideline

557 Ultrasonographic predictors for development of joint damage in rheumatoid arthritis patients: a single joint prospective study Clinical and Experimental Rheumatology Online, January 4, 2013    Clinical Guideline

558 Utility of combined high-resolution bone SPECT and MRI for the identification of rheumatoid arthritis patients with high-risk for erosive progression European Journal of Radiology, January 3, 2013    Clinical Article

559 Fas/FasL promoter gene polymorphism in patients with rheumatoid arthritis Full Text Rheumatismo, January 3, 2013

560 Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients Full Text Rheumatismo, January 3, 2013

50 available pages First Previous 28 29 30 31 32 33 34 35 36 37 Next Last

Clinical Pearls in Rheumatology

Highlights in Rheumatology

ACPA correlate with disease progression in JIA

In a study involving 74 patients with juvenile idiopathic arthritis (JIA), 26 patients had detectable anti-citrullinated protein antibodies (ACPA). The ACPA titers correlated with disease progression at baseline and after a median follow-up of 11.5 months. In addition to predicting disease severity and progression, the authors concluded that ACPA were superior to IgM-RF in diagnosing JIA.

Read the article summary

Predicting cardiovascular mortality in SLE

In a study involving 208 patients with SLE followed for 12 years, 42 deaths occurred, 48% of which were considered to be cardiovascular mortalities. Age, increased cystatin C levels, and arterial disease were predictive of all-cause mortality. Cigarette smoking and increased sVCAM-1, hsCRP, abeta2GP1, and aPL antibody levels were predictive of cardiovascular mortality.

Read the article summary

Anti-apoA-1 antibodies predict cardiovascular disease in RA patients

In a study conducted at the University of Geneva involving 118 patients with rheumatoid arthritis, but without cardiovascular disease at baseline, the 10-year Framingham cardiovascular risk score (FRS) was improved with the inclusion of the anti-apoA-1 antibody titer. The median follow-up was 9 years and the incidence of cardiovascular disease was 16%. Other biomarkers, including the NT-proBNP, oxLDL, CRP, and RF levels and the anti-citrullinated peptide antibody titer, did not improve the FRS.

Read the article summary

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Most Popular Rheumatology Articles

Last month's top read Top Articles of 2012

1 The new European League Against Rheumatism/American College of Rheumatology diagnostic criteria for rheumatoid arthritis: how are they performing Current Opinion in Rheumatology, April 4, 2013

2 EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis Annals of Rheumatic Diseases, April 10, 2013

3 New methods for determining comparative effectiveness in rheumatoid arthritis Current Opinion in Rheumatology, April 3, 2013

4 Rheumatoid arthritis in the elderly: recent advances in understanding the pathogenesis, risk factors, comorbidities and risk-benefit of treatments Aging Health, April 11, 2013    Review Article

5 Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis Annals of Rheumatic Diseases, April 22, 2013    Evidence Based Medicine    Review Article

6 Clinical Response Within 12 Weeks as a Predictor of Future Low Disease Activity in Patients with Early RA: Results from the TEAR Trial The Journal of Rheumatology, April 18, 2013

7 Long-term therapeutic effects and safety of tacrolimus added to methotrexate in patients with rheumatoid arthritis Rheumatology International, April 5, 2013

8 Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study The Journal of Rheumatology, April 2, 2013

9 The impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis (RA) vs. non-RA subjects: Results from a population-based study Arthritis Care & Research , April 17, 2013

10 Treatment strategies for early rheumatoid arthritis Current Opinion in Rheumatology, April 1, 2013

11 Safety of Rituximab in Combination with Other Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: An Open-label Study The Journal of Rheumatology, April 2, 2013

12 Association between testosterone levels and risk of future rheumatoid arthritis in men: a population-based case-control study Annals of Rheumatic Diseases, April 9, 2013

13 Does Acetaminophen Activate Endogenous Pain Inhibition in Chronic Fatigue Syndrome/Fibromyalgia and Rheumatoid Arthritis? A Double-Blind Randomized Controlled Cross-over Trial Pain Physician, March 25, 2013    Free full text

14 Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data Modern Rheumatology, April 9, 2013

15 Adalimumab: 8 years of experience in rheumatoid arthritis International Journal of Clinical Rheumatology, April 2, 2013

16 A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis Rheumatology, April 19, 2013

17 What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review Annals of Rheumatic Diseases, April 23, 2013    Evidence Based Medicine    Review Article

18 Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program The Journal of Rheumatology, April 16, 2013

19 Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial Annals of Rheumatic Diseases, April 8, 2013

20 Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States Arthritis Care & Research , April 2, 2013

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore

Other Topics in Rheumatology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close